208 related articles for article (PubMed ID: 27835676)
1. Serum Carbohydrate Antigen 19-9 in Differential Diagnosis of Benign and Malignant Pancreatic Cystic Neoplasms: A Meta-Analysis.
Cao S; Hu Y; Gao X; Liao Q; Zhao Y
PLoS One; 2016; 11(11):e0166406. PubMed ID: 27835676
[TBL] [Abstract][Full Text] [Related]
2. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis.
Su SB; Qin SY; Chen W; Luo W; Jiang HX
World J Gastroenterol; 2015 Apr; 21(14):4323-33. PubMed ID: 25892884
[TBL] [Abstract][Full Text] [Related]
3. Lymphoepithelial cysts of the pancreas. Can preoperative imaging distinguish this benign lesion from malignant or pre-malignant cystic pancreatic lesions?
Kavuturu S; Sarwani NE; Ruggeiro FM; Deshaies I; Kimchi ET; Kaifi JT; Staveley-O'Carroll KF; Gusani NJ
JOP; 2013 May; 14(3):250-5. PubMed ID: 23669473
[TBL] [Abstract][Full Text] [Related]
4. Macrophage inhibitory cytokine-1 versus carbohydrate antigen 19-9 as a biomarker for diagnosis of pancreatic cancer: A PRISMA-compliant meta-analysis of diagnostic accuracy studies.
Yang Y; Yan S; Tian H; Bao Y
Medicine (Baltimore); 2018 Mar; 97(9):e9994. PubMed ID: 29489701
[TBL] [Abstract][Full Text] [Related]
5. The Feasibility of Serum Multiple Tumor Markers Test Between Patients with Primary Pancreatic Cancer and Those with Benign Pancreatic Cystic Disease.
Lee JH
Clin Lab; 2019 Oct; 65(10):. PubMed ID: 31625360
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of diagnostic value of serum Carbohydrate antigen 199 in pancreatic cancer.
Zhang Y; Jiang L; Song L
Minerva Med; 2016 Feb; 107(1):62-9. PubMed ID: 26824636
[TBL] [Abstract][Full Text] [Related]
7. Macrophage inhibitory cytokine-1/growth differentiation factor-15 in premalignant and neoplastic tumours in a high-risk pancreatic cancer cohort.
O'Neill RS; Emmanuel S; Williams D; Stoita A
World J Gastroenterol; 2020 Apr; 26(14):1660-1673. PubMed ID: 32327914
[TBL] [Abstract][Full Text] [Related]
8. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
[TBL] [Abstract][Full Text] [Related]
9. Cyst carcinoembryonic antigen in differentiating pancreatic cysts: a meta-analysis.
Ngamruengphong S; Bartel MJ; Raimondo M
Dig Liver Dis; 2013 Nov; 45(11):920-6. PubMed ID: 23790480
[TBL] [Abstract][Full Text] [Related]
10. Serum CA 19-9 in the management of cystic lesions of the pancreas.
Fernández-del Castillo C; Alsfasser G; Targarona J; Brugge WR; Warshaw AL
Pancreas; 2006 Mar; 32(2):220. PubMed ID: 16552345
[No Abstract] [Full Text] [Related]
11. Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis.
Huang Z; Liu F
Tumour Biol; 2014 Aug; 35(8):7459-65. PubMed ID: 24789274
[TBL] [Abstract][Full Text] [Related]
12. Analysis of cyst size and tumor markers in the management of pancreatic cysts: support for the original Sendai criteria.
Hoffman RL; Gates JL; Kochman ML; Ginsberg GG; Ahmad NA; Chandrasekhara V; Furth EE; Vollmer CM; Drebin JA
J Am Coll Surg; 2015 Jun; 220(6):1087-95. PubMed ID: 25868415
[TBL] [Abstract][Full Text] [Related]
13. Serum tumor markers and cyst fluid analysis are useful for the diagnosis of pancreatic cystic tumors.
Sperti C; Pasquali C; Guolo P; Polverosi R; Liessi G; Pedrazzoli S
Cancer; 1996 Jul; 78(2):237-43. PubMed ID: 8673998
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of EUS elastography in differentiation of benign and malignant solid pancreatic masses: a meta-analysis.
Pei Q; Zou X; Zhang X; Chen M; Guo Y; Luo H
Pancreatology; 2012; 12(5):402-8. PubMed ID: 23127527
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of Fukuoka and American Gastroenterological Association Guidelines for Predicting Advanced Neoplasia in Pancreatic Cyst Neoplasm: A Meta-Analysis.
Wu J; Wang Y; Li Z; Miao H
Ann Surg Oncol; 2019 Dec; 26(13):4522-4536. PubMed ID: 31617119
[TBL] [Abstract][Full Text] [Related]
16. A prospective multicenter trial evaluating diagnostic validity of multivariate analysis and individual serum marker in differential diagnosis of pancreatic cancer from benign pancreatic diseases.
Hayakawa T; Naruse S; Kitagawa M; Ishiguro H; Kondo T; Kurimoto K; Fukushima M; Takayama T; Horiguchi Y; Kuno N; Noda A; Furukawa T
Int J Pancreatol; 1999 Feb; 25(1):23-9. PubMed ID: 10211418
[TBL] [Abstract][Full Text] [Related]
17. Validation of Sendai and Fukuoka consensus guidelines in predicting malignancy in patients with preoperatively diagnosed mucinous pancreatic cystic neoplasms.
Zhou W; Xu Y; Rong Y; Wu W; Kuang T; Xin B; Zhu H; Lou W; Wang D
J Surg Oncol; 2018 Mar; 117(3):409-416. PubMed ID: 29044541
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of pancreatobiliary cancer from benign biliary strictures using neutrophil gelatinase-associated lipocalin.
Budzynska A; Nowakowska-Dulawa E; Marek T; Boldys H; Nowak A; Hartleb M
J Physiol Pharmacol; 2013 Feb; 64(1):109-14. PubMed ID: 23568978
[TBL] [Abstract][Full Text] [Related]
19. How useful are clinical, biochemical, and cross-sectional imaging features in predicting potentially malignant or malignant cystic lesions of the pancreas? Results from a single institution experience with 220 surgically treated patients.
Goh BK; Tan YM; Thng CH; Cheow PC; Chung YF; Chow PK; Wong WK; Ooi LL
J Am Coll Surg; 2008 Jan; 206(1):17-27. PubMed ID: 18155564
[TBL] [Abstract][Full Text] [Related]
20. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
